Agency Business briefs

Share this article:
imc² formalized its healthcare marketing capability with the launch of imc² health & wellness, an agency focused on pharmaceutical, biotech, device, medical education and health and wellness clients. The agency's clients include GlaxoSmithKline, Pfizer, Shire, Serono, Johnson & Johnson, Millennium and others.

CRM agency MicroMass hired Richard Patterson as vice president, group account director. Patterson is responsible for leading the agency's oncology business. He will report to John Grunstein, executive vice president, client services. Patterson joins from Patterson Consulting Group which he founded in 2003.

The Interpublic Group (IPG) instituted a Kluster desktop application across its 17,000 employee network. IPG will use the Kluster Agency Edition software to facilitate collaboration across its offices and divisions worldwide.

Sudler & Hennessey expanded its presence in China through parent WPP's purchase of a majority stake in MDS Healthcare, a leading agency headquartered in Shanghai. MDS Healthcare employs a staff of 50, and its clients include Pfizer, Bayer, Sanofi-Aventis, among others.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?